Supportive Therapy for Secondary Myelofibrosis

Core Components of Supportive Care

The National Comprehensive Cancer Network recommends administering RBC transfusions (leukocyte-reduced) for symptomatic anemia, maintaining hemoglobin ≥8 g/dL in stable patients, or 9-10 g/dL in those with cardiovascular comorbidities or poor functional tolerance 1, 2, 3
The National Comprehensive Cancer Network suggests considering administering sufficient RBC units over 2-3 days to increase hemoglobin above 10 g/dL to limit chronic anemia effects on quality of life 1
The National Comprehensive Cancer Network advises using CMV-negative blood products whenever possible for CMV-negative recipients 1, 2
The National Comprehensive Cancer Network recommends irradiating all directed-donor products and transfusions for potential stem cell transplant candidates 1, 2
The National Comprehensive Cancer Network suggests providing platelet transfusions for severe thrombocytopenia or active thrombocytopenic bleeding 1, 2, 3
Consider aminocaproic acid or other antifibrinolytic agents for bleeding refractory to platelet transfusions or profound thrombocytopenia 1, 2

The National Comprehensive Cancer Network recommends administering G-CSF or GM-CSF for neutropenic patients with recurrent or resistant bacterial infections 1, 2

The National Comprehensive Cancer Network advises monitoring serum ferritin levels in chronically transfused patients, as iron overload contributes to increased mortality and morbidity 1, 2
Recognize that increased non-transferrin-bound iron generates toxic hydroxyl and oxygen radicals causing lipid peroxidation and organ damage to liver, heart, and endocrine organs 1
RBC transfusion requirement itself is a negative prognostic factor in myeloproliferative disorders 1

Initiate broad-spectrum antibiotics immediately for any fever or symptoms of infection in neutropenic patients 4
Add G-CSF during severe active infections with neutropenia, even though prophylactic use is not routinely recommended 4

The National Comprehensive Cancer Network recommends providing clinical monitoring, psychosocial support, and quality-of-life assessment addressing physical, functional, emotional, spiritual, and social domains 1, 2, 3
Monitor for transfusion-related complications including citrate toxicity (hypocalcemia, hypomagnesemia) when multiple units are given rapidly 4
Reassess hemoglobin levels and symptoms after each transfusion unit 4